Zhang Lingyue, Cao Zuoyuan, Yang Yeying, Tan Xinyi, Mao Jianchun, Su Li
Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Medicine (Baltimore). 2020 Jun 12;99(24):e20642. doi: 10.1097/MD.0000000000020642.
Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease associated with progressive joint damage and disability. There is a lack of effective methods in the treatment of RA currently. Many clinical trials have proved that traditional Chinese medicine (TCM) has obvious advantages in the treatment of RA. In this systematic review, we intend to evaluate the efficacy and safety of TCM for active RA.
We will search PubMed, the Cochrane Library, Embase, Web of Science, the Chinese National Knowledge Infrastructure Database, Wanfang Data, and Chinese Science and Technology Periodical Database. Simultaneously we will retrieval relevant meeting minutes, eligible research reference lists, symposium abstracts, and grey literatures. Included criteria are randomized controlled trials (RCTs) about TCM for active RA to assess its efficacy and safety. We will use the Revman 5.3 and Stata 13.0 software for data synthesis, sensitivity analysis, meta regression, subgroup analysis, and risk of bias assessment. The Grading of Recommendations Assessment, Development, and Evaluation standard will be used to evaluate the quality of evidence.
This systematic review will provide a synthesis of TCM for patients with active RA from various evaluation aspects including tender joint count, swollen joint count, RF, CRP, ESR, DAS28, TCM syndrome evaluation criteria, and adverse events.
The systematic review will provide evidence to assess the efficacy and safety of TCM in the treatment of patients with active RA.
PROSPERO CRD42019146726.
类风湿关节炎（RA）是一种慢性全身性自身免疫性疾病，与进行性关节损伤和残疾相关。目前在类风湿关节炎的治疗中缺乏有效的方法。许多临床试验已证明，中医（TCM）在类风湿关节炎的治疗中具有明显优势。在本系统评价中，我们旨在评估中医治疗活动期类风湿关节炎的疗效和安全性。
我们将检索PubMed、Cochrane图书馆、Embase、Web of Science、中国国家知识基础设施数据库、万方数据和中国科技期刊数据库。同时，我们将检索相关会议记录、符合条件的研究参考文献列表、研讨会摘要和灰色文献。纳入标准为关于中医治疗活动期类风湿关节炎以评估其疗效和安全性的随机对照试验（RCT）。我们将使用Revman 5.3和Stata 13.0软件进行数据合成、敏感性分析、meta回归、亚组分析和偏倚风险评估。推荐评估、制定和评价标准将用于评估证据质量。
本系统评价将从多个评估方面对活动期类风湿关节炎患者的中医治疗进行综合分析，包括压痛关节计数、肿胀关节计数、类风湿因子（RF）、C反应蛋白（CRP）、红细胞沉降率（ESR）、疾病活动度评分28（DAS28）、中医证候评估标准和不良事件。
本系统评价将为评估中医治疗活动期类风湿关节炎患者的疗效和安全性提供证据。
PROSPERO CRD42019146726。
